Multivariate analysis of outcome in patients with normal karyotype
. | All patients with normal karyotype . | . | . | . | Patients with normal karyotype, 60 y or younger . | . | . | . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | OS . | . | DFS . | . | OS . | . | DFS . | . | ||||||
. | P . | OR (95% Cl) . | P . | OR (95% Cl) . | P . | OR (95% Cl) . | P . | OR (95% Cl) . | ||||||
| Age, 60 y or younger vs older than 60 y | <.001 | 1.69 (1.38-2.07) | <.001 | 1.94 (1.42-2.66) | — | — | — | — | ||||||
| NPM1-FLT3 group* | ||||||||||||||
| NPM1-mut/FLT3-ITDneg | .043 | 0.76 (0.59-0.99) | .036 | 0.66 (0.45-0.97) | .019 | 0.63 (0.43-0.93) | .009 | 0.49 (0.29-0.84) | ||||||
| NPM1-mut/FLT3-ITDpos | NS | NS | NS | NS | ||||||||||
| NPM1-wt/FLT3-ITDpos | NS | .006 | 2.02 (1.22-3.34) | NS | NS | |||||||||
| WBC count* | ||||||||||||||
| Intermediate (>9.2 ≤ 21.7 GPT/L) | NS | NS | NS | NS | ||||||||||
| Highest, 21.7 or more GPT/L | .002 | 1.87 (1.25-2.79) | .001 | 2.25 (1.40-3.63) | .006 | 1.66 (1.15-2.34) | .019 | 1.86 (1.11-3.13) | ||||||
| De novo AML versus sAML | NS | .039 | 0.53 (0.29-0.97) | NS | NS | |||||||||
. | All patients with normal karyotype . | . | . | . | Patients with normal karyotype, 60 y or younger . | . | . | . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | OS . | . | DFS . | . | OS . | . | DFS . | . | ||||||
. | P . | OR (95% Cl) . | P . | OR (95% Cl) . | P . | OR (95% Cl) . | P . | OR (95% Cl) . | ||||||
| Age, 60 y or younger vs older than 60 y | <.001 | 1.69 (1.38-2.07) | <.001 | 1.94 (1.42-2.66) | — | — | — | — | ||||||
| NPM1-FLT3 group* | ||||||||||||||
| NPM1-mut/FLT3-ITDneg | .043 | 0.76 (0.59-0.99) | .036 | 0.66 (0.45-0.97) | .019 | 0.63 (0.43-0.93) | .009 | 0.49 (0.29-0.84) | ||||||
| NPM1-mut/FLT3-ITDpos | NS | NS | NS | NS | ||||||||||
| NPM1-wt/FLT3-ITDpos | NS | .006 | 2.02 (1.22-3.34) | NS | NS | |||||||||
| WBC count* | ||||||||||||||
| Intermediate (>9.2 ≤ 21.7 GPT/L) | NS | NS | NS | NS | ||||||||||
| Highest, 21.7 or more GPT/L | .002 | 1.87 (1.25-2.79) | .001 | 2.25 (1.40-3.63) | .006 | 1.66 (1.15-2.34) | .019 | 1.86 (1.11-3.13) | ||||||
| De novo AML versus sAML | NS | .039 | 0.53 (0.29-0.97) | NS | NS | |||||||||
For all patients with normal karyotype, n = 701; for those 60 years old or younger, n = 387.
Not significant (NS) were the following: platelets, LDH (log), sex, MLL-PTD, FLT3-TKD, BM blasts.
— indicates not applicable.
Reference group for NPM1-FLT3 was NPM1-wt/FLT3-ITDneg; for WBC count, those with 9.2 or fewer GPT/L.